F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, vol.395, pp.1054-62, 2020.

J. Yang, Y. Zheng, X. Gou, K. Pu, Z. Chen et al., Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis, Int J Infect Dis, 2020.

C. Wu, X. Chen, Y. Cai, J. Xia, X. Zhou et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, 2020.

L. Zhang, F. Zhu, L. Xie, C. Wang, J. Wang et al., Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China, Ann Oncol, 2020.

D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

W. Liang, W. Guan, R. Chen, W. Wang, J. Li et al., Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol, vol.21, pp.335-342, 2020.

L. Ran, X. Chen, Y. Wang, W. Wu, L. Zhang et al., Risk factors of healthcare workers with corona virus disease 2019: a retrospective cohort study in a designated hospital of Wuhan in China, Clin Infect Dis, 2020.

L. Chang, Y. Yan, and L. Wang, Coronavirus disease 2019: coronaviruses and blood safety, Transfus Med Rev, 2020.

M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, vol.30, pp.269-71, 2020.

T. P. Sheahan, A. C. Sims, S. R. Leist, A. Schafer, J. Won et al., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat Commun, vol.11, p.222, 2020.

C. J. Gordon, E. P. Tchesnokov, J. Y. Feng, D. P. Porter, and M. Gotte, The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus, J Biol Chem, 2020.

B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, 2020.

X. Yao, F. Ye, M. Zhang, C. Cui, B. Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, 2020.

J. Liu, R. Cao, M. Xu, X. Wang, H. Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, vol.6, p.16, 2020.

X. Zhang, K. Song, F. Tong, M. Fei, H. Guo et al., First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab, Blood Adv, vol.4, pp.1307-1317, 2020.

C. Zhang, Z. Wu, J. W. Li, H. Zhao, and G. Q. Wang, The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality, Int J Antimicrob Agents, vol.2020, p.105954

H. Zhang, J. M. Penninger, Y. Li, N. Zhong, and A. S. Slutsky, Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target, Intensive Care Med, vol.46, pp.586-90, 2020.

M. Vaduganathan, O. Vardeny, T. Michel, J. Mcmurray, M. A. Pfeffer et al., Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19, N Engl J Med, 2020.

P. Zhang, L. Zhu, J. Cai, F. Lei, J. Qin et al., Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertenison hospitalized with COVID-19, Circ Res, 2020.

J. R. Wingard, A. K. Leahigh, D. Confer, J. Edwards, R. L. Billups et al., Preparing for the unthinkable: emergency preparedness for the hematopoietic cell transplant program, Biol Blood Marrow Transpl, vol.12, pp.1229-1267, 2006.